Pancreatic cancer is related to a very weak diagnosis; the close parallel between disease incidence and mortality rates from pancreatic cancer reflects the fatal nature of this disease. Although early detection procedures are growing, they are not applicable yet for pancreatic cancer. The majority of cancer patients suffer from advanced disease, in which surgery has no potential effect. Based on the growing evidence, it is predicated that cancer immunotherapy alone or in combination will probably be an essential section of different cancer treatment methods. There are different kinds of immune processes, including various antitumour and tumour‐promoting leukocytes. Moreover, tumour cells utilise numerous approaches to overwhelm the immune response. Use of antibody in the therapeutic protocols is proving significant success and is probably a key element of cancer treatment. This method is directed against numerous negative immunologic regulators and immune checkpoints. In the present review, the clinical outlines of immune checkpoint inhibition are discussed in pancreatic cancer.

中文翻译：

---

靶向免疫检查点：在胰腺癌联合治疗中构建更好的治疗难题。

胰腺癌与非常薄弱的​​诊断有关；胰腺癌的发病率和死亡率之间的密切联系反映了这种疾病的致命性质。尽管早期检测程序正在增长，但它们尚不适用于胰腺癌。大多数癌症患者患有晚期疾病，其中手术没有潜在影响。根据越来越多的证据，可以预测单独或联合使用癌症免疫疗法可能会成为不同癌症治疗方法的重要组成部分。有不同种类的免疫过程，包括各种抗肿瘤和促肿瘤白细胞。此外，肿瘤细胞利用多种方法来压制免疫反应。在治疗方案中使用抗体已证明取得了重大成功，并且可能是癌症治疗的关键要素。该方法针对许多负免疫调节剂和免疫检查点。在本综述中，免疫检查点抑制的临床概述在胰腺癌中进行了讨论。